TY - JOUR
T1 - Administering the HPV Vaccine to People Living with HIV
T2 - Providers’ Perspectives
AU - Koskan, Alexis
AU - Brennhofer, Stephanie A.
AU - Helitzer, Deborah
N1 - Funding Information:
This work was supported by the Arizona Area Health Education Centers (AHEC) Program.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - HIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients’ perspectives about the HPV vaccine. However, little is known about their healthcare practitioners’ vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians’ HPV vaccination behaviors, HIV patient’s willingness to get the HPV vaccine, the role of HIV-positive patients’ immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients’ CD4 count in terms of timing of HPV vaccine administration; some believed that patients’ immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration’s recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer.
AB - HIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients’ perspectives about the HPV vaccine. However, little is known about their healthcare practitioners’ vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians’ HPV vaccination behaviors, HIV patient’s willingness to get the HPV vaccine, the role of HIV-positive patients’ immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients’ CD4 count in terms of timing of HPV vaccine administration; some believed that patients’ immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration’s recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer.
KW - Anal cancer
KW - HIV/AIDS
KW - Healthcare practitioners
KW - Human papillomavirus (HPV)
KW - Qualitative research
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85087426553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087426553&partnerID=8YFLogxK
U2 - 10.1007/s10935-020-00598-w
DO - 10.1007/s10935-020-00598-w
M3 - Article
C2 - 32613520
AN - SCOPUS:85087426553
SN - 0278-095X
VL - 41
SP - 349
EP - 362
JO - Journal of Primary Prevention
JF - Journal of Primary Prevention
IS - 4
ER -